Church & Dwight (CHD) Teardown: The Write-Down Habit

$6.2 billion of revenue. $1.2 billion in operating cash flow. A 44.7% gross margin earned on baking soda, cat litter, condoms, dry shampoo, acne patches, and water flossers. A dividend raised every year for 25+ years. Church & Dwight (NYSE: CHD) is one of the steadier compounders in consumer staples - until you look at what it costs to buy the growth the core business cannot generate on its own.

Between FY2022 and FY2024, Church & Dwight recorded $768M in pre-tax impairment charges on two acquired brands: $411.0M on Finishing Touch Flawless (FY2022), and $357.1M on VitaFusion / Lil Critters vitamins (FY2024). Both businesses were subsequently exited or divested. Including exit charges and the VMS divestiture loss, the cumulative pre-tax cost of those two acquisitions exceeded $872M. Both were bought at premium prices during category growth waves. Both collapsed when the category matured or commoditized faster than CHD's integration could offset.

In July 2025, Church & Dwight paid approximately $815M to acquire Touchland - a premium hand sanitizer brand with roughly $115M in 2024 revenue and COVID-era growth tailwinds. The compounder's newest power brand is the next M&A test. This teardown reads the record to understand whether that test is likely to pass.

Section 1 - The snapshot

Metric	FY2025	Q1 FY2026 (most recent)	Q1 FY2025 (prior year)
Net sales	$6,203.2M	$1,469.3M	$1,467.1M
Revenue YoY (reported)	+1.6%	+0.2%	n/a
Revenue YoY (organic)	+0.7%	+5.0%	n/a
Gross margin	44.7%	46.4%	45.0%
Operating income	$1,077.6M (17.4%)	$291.0M (19.8%)	$295.3M (20.1%)
Net income	$736.8M	$216.3M	$220.1M
Diluted EPS (GAAP)	$3.02	$0.91	$0.89
Adjusted diluted EPS	$3.53	$0.95	n/a
Operating cash flow	$1,215.4M	$174.8M	$185.7M
Total long-term debt	$2,205.1M	$2,205.7M	n/a
Cash	$409.0M	$503.4M	n/a
Net debt (approx.)	~$1,796M	~$1,702M	n/a
Share buybacks	$900.0M	n/a (not separately stated)	n/a
Dividend per share	$1.18	$0.3075/quarter (increased Jan 2026)	n/a

The five-year arc shows the steady compounder with two impairment-year disruptions:

Fiscal year	Net sales	Reported growth	Gross margin	Operating income	Operating margin	Key event
FY2021	$5,190.1M	+6.0%	43.6%	$1,079.1M	20.8%	TheraBreath acquired Dec 2021
FY2022	$5,375.6M	+3.6%	41.9%	$597.8M	11.1%	Flawless $411.0M impairment; Hero acquired Oct 2022
FY2023	$5,867.9M	+9.2%	44.1%	$1,057.4M	18.0%	Strong rebound; no major impairments
FY2024	$6,107.1M	+4.1%	45.7%	$807.1M	13.3%	VMS $357.1M impairment; Graphico acquired
FY2025	$6,203.2M	+1.6%	44.7%	$1,077.6M	17.4%	Portfolio rationalization; Touchland acquired

Segment	FY2021	FY2022	FY2023	FY2024	FY2025	FY2025 % of total
Consumer Domestic	$3,941.9M	$4,131.0M	$4,571.2M	$4,732.3M	$4,774.8M	77%
Consumer International	$912.2M	$896.1M	$975.7M	$1,071.5M	$1,129.4M	18%
Specialty Products (SPD)	$336.0M	$348.5M	$321.0M	$303.3M	$299.0M	5%
Total	$5,190.1M	$5,375.6M	$5,867.9M	$6,107.1M	$6,203.2M	100%

Section 2 - The business model: how they actually make money

Church & Dwight is a branded CPG manufacturer, not a DTC company. Its products reach consumers through mass retail, grocery chains, drug stores, and e-commerce - primarily via Walmart (approximately 23% of consolidated net sales in each of FY2025, FY2024, and FY2023, per the 10-K). Top four customers account for approximately 44% of net sales. Online channels represent 21.4% of consumer sales (per the FY2025 10-K MD&A); direct-to-consumer is a small fraction of that.

The business model rests on a value-and-premium barbell. Arm & Hammer is the value anchor - a 180-year-old brand with genuinely inelastic demand across laundry detergent, cat litter, baking soda, and dental care. OxiClean and Trojan add scale in adjacent categories. These brands have never been impaired and continue to compound at low-single-digit organic growth rates. They generate the excess cash that funds M&A.

The premium layer is what CHD buys: Batiste (world's #1 dry shampoo), TheraBreath (#1 alcohol-free mouthwash in the US, acquired December 2021), Hero / Mighty Patch (#1 acne patch brand, acquired October 2022), and now Touchland (#1 premium hand sanitizer, acquired July 2025). The seven power brands together represent approximately 70% of CHD's net sales and profits per the FY2025 10-K.

Where does the 44.7% gross margin come from? Brand-equity pricing power - a consumer buying Arm & Hammer laundry detergent or Mighty Patch acne patches is not price-shopping against private label in the same way they would for commodity products. Productivity programs add roughly 100-160bps annually through supply-chain optimization. The FY2024 gross margin peak at 45.7% also benefited from a one-time tariff refund that did not repeat in FY2025.

The Specialty Products Division (SPD, $299.0M, 5% of revenue) sells sodium bicarbonate into industrial, institutional, and food applications through B2B wholesale contracts. It is stable, unexciting, and not the story.

Here is what some of CHD's growth brands look like on social, where brand health shows up before it appears in the financials:

@magdalenalook

#yearofhorse #dryshampoo #nowashday #hair @Batiste

♬ L.Delibes, Sylvia - Pizzicato - AllMusicGallery

@magdalenalook, 3.2M plays, 32.1K likes. Organic Batiste dry shampoo content hitting 3M+ plays - the brand generates genuine user demand at scale, which is the social proof a power brand needs. Social signal only.

@selina.dasilvaaa

4 step teeth cleaning + whitening routine ad|products: @TheraBreath US whitening fresh breath oral rinse #teethwhitening #oralhygiene

♬ Sunday - HNNY

@selina.dasilvaaa, 1.3M plays, 61.7K likes. A paid TheraBreath partnership post in a multi-step teeth routine - the brand is buying reach in the oral care category against Sensodyne and Crest, which is exactly the right competitive play for a #1 alcohol-free mouthwash. Social signal only.

@blowoutprofessor

Batiste is basically the easy bake oven of dry shampoo. It looks like it should work… but compared to real salon-quality dry shampoo it barely does anything.

♬ original sound - Chris Wenzel

@blowoutprofessor, 543K plays, 16.8K likes. A critical Batiste review from a professional stylist - this is the competitive threat that power brands face when higher-end alternatives gain distribution. Social signal only.

Section 3 - Strengths: the moat that is real

1. The Arm & Hammer / OxiClean core is a genuine compounder with pricing power and no impairment history. Arm & Hammer baking soda has been sold since 1846. The brand anchors multiple use cases - laundry detergent, cat litter, baking soda, toothpaste, and deodorizing products - that are habitual, non-discretionary, and private-label-resistant at the value end of the market. OxiClean adds stain-fighting premium positioning. Together, these two brands plus Trojan have never required an impairment charge. In FY2025, Consumer Domestic Household Products (the primary Arm & Hammer / OxiClean category) generated $2,556.9M in revenue with consistent gross margin contribution. This core is what makes CHD a compounder: it generates the excess cash ($1,215.4M FY2025 operating cash flow) that funds everything else. Source: CHD 10-K FY2025, segment and product line tables.

2. Operating cash flow hit a 5-year high in FY2025 at $1,215.4M, supporting a $900M buyback and a 25+-year dividend growth streak. Even in the two impairment years (FY2022: $885.2M OCF; FY2024: $1,156.2M OCF), operating cash flow remained strong because impairments are non-cash charges that don't reduce actual cash generation from the portfolio. CHD has raised its annual dividend every year for 25+ consecutive years - the definition of a Dividend Aristocrat. The FY2025 dividend was $1.18/share; the $900M buyback was the largest capital return program in recent history, reducing shares outstanding from approximately 246M to 237M. Total cash returned in FY2025: approximately $1,187M. Source: CHD 10-K FY2025; CHD 10-K filings FY2021-FY2025.

3. The growth brands - Hero, TheraBreath, Batiste, Touchland - have genuine category-leadership positions. Hero / Mighty Patch is the #1 acne patch brand in the US and is growing in Europe, Canada, and Asia. TheraBreath is the #1 alcohol-free mouthwash and is driving international oral care expansion. Batiste is the world's #1 dry shampoo. These are not generic household names - they are category-defining brands with strong repeat-purchase economics and growing online demand. The Item 1A Risk Factor arc from the Item 1A risk-factor sections of the FY2023-FY2025 10-Ks confirms these brands have not appeared in any impairment discussion. Consumer International grew +5.4% in FY2025, with Hero, TheraBreath, Batiste, and OxiClean cited as primary drivers. Source: CHD 10-K FY2025, segment MD&A.

4. A 66% premium / 34% value brand mix gives pricing power optionality that pure value CPG players lack. CHD's own FY2025 filing discloses the portfolio is 66% premium brands and 34% value brands of worldwide consumer revenue. That premium skew means CHD captures both the trade-down consumer (Arm & Hammer detergent at value pricing) and the trade-up consumer (Mighty Patch, TheraBreath, Touchland). Few consumer staples companies at CHD's scale have this barbell structure working across two distinct consumer demand curves simultaneously. Source: CHD FY2025 10-K, strategic brand portfolio disclosures; sell-side research notes and dated financial press (linked below).

Section 4 - Weaknesses: the cracks in the 10-Q

1. The M&A impairment tail: $768M in non-cash charges over two years, both businesses subsequently exited. This is not a one-time anomaly. It is a pattern. The pattern: CHD acquires into a growing consumer category at a premium multiple, holds the brand through the category's peak, and then records a large non-cash impairment when the category matures or competition overwhelms the brand's moat. Finishing Touch Flawless - a hair-removal brand acquired in 2019 - generated $411.0M in impairment charges in FY2022 when inflation hit discretionary spending and a major retailer discontinued certain Flawless products. VitaFusion and Lil Critters - a vitamins, minerals, and supplements brand riding the COVID health wave - generated $357.1M in impairment charges in FY2024 when the category attracted 35+ new entrants including aggressive private-label competitors (10 significant competitors a decade ago to 50+ by 2024 per CHD 10-K filings). Including the subsequent VMS divestiture loss ($58.5M pre-tax) and Flawless/Spinbrush/Waterpik exit charge ($45.6M pre-tax), the total pre-tax cost of the two failed acquisition tracks exceeded $872M. The FY2025 10-K is direct: "Any impairment charges could adversely affect the Company's financial condition, margins and results of operations." This is not generic boilerplate - it is a company describing a demonstrated outcome. Source: CHD 10-K FY2022 (Flawless impairment); CHD 10-K FY2024 (VMS impairment); CHD 10-K FY2025, Item 1A Risk Factors.

2. Organic underlying growth was only +0.7% in FY2025 - and private-label pressure is now disclosed as hitting named categories. Strip out the Touchland acquisition contribution (+1.9%) and the portfolio exit headwind (-1.0%), and the reported +1.6% becomes +0.7% organic volume and price/mix. Price/mix was -0.1% - the first negative price print in recent years. More alarming than the aggregate is the category-level disclosure. The FY2025 10-K Item 1A states verbatim: "customers have discontinued or reduced distribution of some of our products to encourage those consumers to purchase the customers' less expensive and, in some cases, more profitable private label and retail-branded products (primarily in the stain fighters, diagnostic kits and oral analgesics categories)." That names OxiClean (stain fighters), First Response (diagnostic kits), and Orajel (oral analgesics) as active private-label displacement targets. And in a disclosure that did not appear in prior years: "In 2025, some of our largest customers launched private label brands that compete with our products." The VMS collapse began with exactly this dynamic. Source: CHD 10-K FY2025, Item 1A Risk Factors.

3. Touchland: a $815M bet on a COVID-era brand with category-volume and seasonality risk. Church & Dwight paid $656M cash plus $159M contingent earnout - approximately 7x Touchland's 2024 annual net sales of approximately $115M - for a premium hand sanitizer brand. The premium is justified by Touchland's #1 category position and strong DTC/social presence. The risk: hand sanitizer category volume rose dramatically during COVID (2020-2021) and has since normalized. Touchland has sustained revenue growth through premiumization and brand building, but the category's secular demand trajectory is unclear post-COVID. The FY2025 10-K Item 1A explicitly identifies Touchland's integration as a risk: "In 2025, we exited from the Flawless, Spinbrush, Waterpik showerhead businesses and divested of our VMS business." The same paragraph names the "acquisition impairment and divestiture execution risk" as a headline risk factor - directly referencing the company's own demonstrated pattern of buying trend-sensitive brands and then writing them off. The earnout structure ($159M payable H1 2026 based on Touchland's 2025 net sales) suggests CHD acknowledged demand uncertainty even at deal close. Source: CHD 10-K FY2025, Item 1A Risk Factors; acquisition notes.

4. Tariff-driven manufacturing disruption on Waterpik threatens a power brand's supply chain. Waterpik is one of seven power brands, representing a meaningful share of the Consumer Domestic personal care category. The FY2025 10-K and Q1 2026 10-Q disclose that CHD has "substantially ceased the import of substantially all Waterpik flossers and certain other products from China into the U.S." in response to tariff escalation. Manufacturing is being shifted and relocated, a process that carries ramp-up costs, quality risk, and unit-cost pressure during the transition. The Q1 2026 gross margin bridge showed -190bps of tariff and inflation cost headwind - partially offset by productivity programs and the acquisition mix benefit from Touchland. The Q1 2026 10-Q discloses CHD is mitigating by "exiting certain business lines, shifting production and relocating manufacturing operations, finding alternative sources of supply, selectively increasing prices, adjusting inventories, seeking exemptions with respect to tariffs." A power brand navigating a China supply-chain unwinding in a tariff-escalating environment is not a trivial operational challenge. Source: CHD 10-K FY2025, Item 1A; CHD Q1 2026 10-Q, risk factors and MD&A.

Section 5 - Opportunities and threats

The opportunity side of the CHD thesis is clearer after FY2025's portfolio rationalization than it was during the impairment years.

Consumer International is the most straightforward growth lever. The segment grew +5.4% in FY2025 and +3.7% organically in Q1 2026, driven by Batiste, Hero, TheraBreath, and OxiClean expanding in Europe, Canada, and Mexico. International is $1,129.4M - 18% of total revenue - against a US consumer base that has matured. CHD's management has articulated a goal of scaling Consumer International from roughly $1B toward $2B through organic growth and targeted M&A (the Graphico Japan distributor acquisition in June 2024 is an example of this approach). Europe (24% of international) and Canada (23%) are the primary near-term vectors; Mexico (8%) and the Global Markets Group distributor network covering 100+ countries represent longer-term optionality.

Within Consumer Domestic, the oral care platform (TheraBreath + Waterpik flosser) represents the clearest category-level scale opportunity. CHD has articulated a goal of building oral care from approximately $1B toward $1.5B globally. TheraBreath is already the #1 alcohol-free mouthwash in the US; its international distribution is still in early innings. The category tailwind of consumer focus on preventive oral health is structural.

The threats are concentrated and some are already materializing.

Private-label displacement is the single most credible structural threat. It is not theoretical - it already destroyed VMS ($357.1M write-off), and the FY2025 10-K explicitly names three additional categories where it is currently happening: stain fighters, diagnostic kits, and oral analgesics. The mechanism is consistent: category growth attracts private-label entrants, retailers allocate shelf to higher-margin store brands, branded volumes decline, and the branded player faces a price-or-volume tradeoff they cannot win without major category investment. The 10-K's statement that "some of our largest customers launched private label brands that compete with our products" in 2025 is a signal that the commodity pressure is accelerating, not stabilizing.

Customer concentration is an explicit filing risk. Walmart at 23% of consolidated net sales is not just a distribution channel - it is a partner with the power to rationalize SKUs, shift shelf space toward store brands, and negotiate pricing. The top four customers (approximately 44% of net sales) have equivalent power in their respective retail formats. CHD's Q1 2026 organic growth of +5.0% was a strong print, but Consumer Domestic reported only -1.1% on a net sales basis because of portfolio exits. A Walmart SKU rationalization or private-label expansion in any of the named categories is a direct revenue threat.

Touchland integration execution risk is the M&A-specific threat for FY2026-FY2027. The brand has strong social presence and premium positioning. The question is whether CHD can maintain Touchland's growth trajectory after acquisition - a historical pattern in which CHD's largest acquired growth brands (Flawless, VMS) eventually underperformed their acquisition multiples. TheraBreath and Hero appear to be the exceptions, not the rule. The burden of proof now falls on Touchland.

Section 6 - The macro environment

Church & Dwight is flying through four macro forces simultaneously.

The consumer staples recession-resistance thesis works for CHD's core. Arm & Hammer laundry detergent, cat litter, and baking soda are not items households cut when incomes compress. OxiClean and Trojan have similar inelastic demand characteristics. This portion of CHD's portfolio - roughly 30-40% of total revenue - is genuinely recession-resistant and gains relative value in a slow-growth consumer environment where private-label competition for truly discretionary categories intensifies.

Tariff escalation in 2025-2026 is the most immediate macro threat with direct P&L exposure. CHD's FY2025 10-K describes the tariff environment as a key source of "commodity cost volatility and economic uncertainty." The Q1 2026 gross margin bridge showed -190bps of tariff and inflation costs. Waterpik flosser manufacturing is being restructured in real time. CFO Lee McChesney flagged a $25-30M Middle East commodity cost headwind on the Q1 2026 call that management believes it can offset with productivity. The FY2026 gross margin expansion target of +100bps requires approximately 340bps of gross margin tailwind (productivity, acquisition mix, volume/price) to overcome approximately 240bps of headwind. That is a tighter outcome than the guidance number suggests.

Generational consumer behavior is an explicit risk factor in the FY2025 10-K - not a generic trend but a named filing disclosure. The 10-K states verbatim: "Generation Z and Generation Alpha who have different spending, consumption and purchasing habits and are increasingly shifting to private label products and new nontraditional brands rather than maintaining allegiance to historical brands." This is the structural demand curve question that CHD's acquired growth brands (Hero, TheraBreath, Touchland) are positioned to address - these are brands younger consumers actually chose over incumbents. But they were each acquired at premiums, and premium multiples require sustained organic growth.

The e-commerce channel shift is both an opportunity and a vulnerability. CHD discloses 21.4% of consumer sales through online channels (per the FY2025 10-K MD&A). That share is growing. The opportunity is that Hero, Touchland, and TheraBreath are brands with strong DTC and Amazon presence. The vulnerability is that e-commerce reduces the shelf-placement moat that traditional CPG brands rely on - a new brand can achieve top-of-search without the distribution relationships that took decades to build. The VMS collapse was partly driven by online-native vitamin brands capturing share from VitaFusion's brick-and-mortar position.

Section 7 - The CFO verdict and the operator bridge

Here is the read on Church & Dwight from a CFO's vantage point.

Where the Street's read sits. The consensus on CHD is a Hold to Cautious Buy, with analyst price targets in the mid-to-high $90s range (implying modest upside from current levels at the time of this writing). The bull case is articulate: iconic Arm & Hammer moat, 44-46% gross margin, $1.2B annual OCF, Dividend Aristocrat status, and a post-rationalization portfolio that is cleaner and more growth-oriented than it was two years ago. Hero and TheraBreath are genuine category leaders with international expansion ahead. Adjusted EPS is guiding +5-8% for FY2026. The bear case is equally articulate: organic underlying growth at +0.7% in FY2025 is anemic for a company trading at a significant consumer staples premium; the M&A playbook has a demonstrated impairment tail; Touchland was acquired at roughly 7x revenue for a COVID-era brand; and private-label pressure is explicitly worsening in named categories. Sell-side research notes and dated financial press (linked below) reflect a split between investors who underwrite the portfolio transformation thesis and those who see FY2026's reported-sales contraction guidance (-1.5% to -0.5%) as evidence the transition is running slower than management's framing suggests.

Where I agree and where I differentiate. The bulls are right about the core. Arm & Hammer is one of the most durable value brands in American consumer staples history. The gross margin is real, the cash flow is real, and the dividend track record is real. A company generating $1.2B in annual operating cash flow with a 44.7% gross margin and net debt of $1.8B is not a distress situation. The bears are right that organic growth is the number that matters for the long-term compounding thesis, and +0.7% underlying is not compelling. Where I differentiate from both: the relevant debate about CHD is not whether the core is good (it is) or whether the last two acquisitions failed (they did). The relevant debate is whether the discipline that governs the acquisition process has actually changed - and the Touchland transaction does not obviously answer that question in the affirmative.

CHD paid approximately $815M for a brand doing $115M in revenue. The theoretical justification is that Touchland has category-leading positioning, growing DTC presence, and strong brand equity. All of that may be true. It was also true of Flawless (premium hair removal, strong retail placement) and VitaFusion (category leader in gummy vitamins, strong household penetration) at the time of acquisition. The tell is not the acquisition rationale - it is the category durability of the demand driving the brand's growth. Flawless grew during COVID at-home grooming and collapsed when discretionary spend tightened. VMS grew during COVID health awareness and collapsed when private-label flooded the category. Hand sanitizer grew during COVID and is now sustained by Touchland's premiumization. The question is whether that premium positioning is structurally durable or whether the category normalize and private-label enters. The FY2025 10-K does not answer that question - it only confirms that CHD paid a premium to find out.

The operator bridge. Your $5-80M brand almost certainly has a version of the CHD pattern in miniature - and it is worth naming, because it shows up in growth-stage brands long before it shows up in the goodwill impairment line.

The CHD pattern is this: a brand with a strong, cash-generative core uses that core's excess cash to buy growth in adjacent categories. The adjacencies that work best look like organic growth from the outside - the acquired brand hits its numbers, grows the top line, and the combined entity looks like a compounder. The acquisitions that fail share a consistent characteristic: they ride a category wave (COVID health awareness, at-home grooming, consumer wellness) that CHD's core business doesn't naturally protect. When the wave reverses, the acquired brand has no structural moat to defend its shelf position or margin profile, because the moat was the category tailwind itself.

I have seen this pattern in client work with $15-40M brands that use a profitable hero SKU to fund adjacency bets. The diagnostic is always the same: look at the organic volume trend of the adjacency SKU separate from the hero. Is it growing on its own purchasing economics, or is it growing because the category is growing? If it's the latter - if you pull the category tailwind and the brand stalls - then what you own is not a brand with a moat, but a category bet with a brand on top of it. CHD's mistake, twice, was not recognizing that distinction before the write-down arrived.

Early-warning scorecard - five lines that catch the CHD pattern 12 months early:

1. Category volume growth vs. brand-level volume growth: if your acquired brand's volume is growing faster than the category average, you have brand share gain. If your brand is growing at or below the category rate, you are riding the wave, not building a moat. Separate the two numbers and track the gap quarterly.
2. Competitive entrant count in the category: VMS went from 10 significant competitors to 50+ in a decade. That number is observable before the impairment. Track how many new SKUs are appearing in your brand's category on Amazon and in retail planograms. An accelerating entrant count in a category you just acquired is the earliest warning of the commoditization cycle that leads to write-downs.
3. Private-label shelf allocation as a percentage of total category facing: retailers' own private-label programs expand when category growth slows and branded premiums are hard to sustain. Monitor your retailer's own-brand SKU count in your category on a quarterly basis. CHD's 10-K now explicitly names three categories where retailer private label is displacing CHD products; by the time that language appears in a 10-K, the trend is 12-18 months old.
4. Gross margin of the acquired brand vs. the portfolio average: if the acquisition is improving consolidated gross margin (as Hero and Touchland appear to be doing), that is evidence of durable premium pricing. If the acquired brand's margin is compressing post-acquisition, it is evidence that the category is normalizing. Require a brand-level gross margin disclosure before any acquisition close, and build a watch threshold of -200bps from acquisition gross margin into your post-close monitoring.
5. Net debt to EBITDA trend over the three years post-acquisition: CHD's net debt to EBITDA is manageable today at roughly 1.5x ($1.8B net debt against approximately $1.2B operating cash flow). But each major M&A move - Hero ($630M), Touchland ($815M) - temporarily pushes net debt to EBITDA higher. If you are buying growth with debt and the acquired brand underperforms, you get a simultaneous revenue shortfall and debt service obligation with no impairment hedge. Build a stress test: what is the net debt to EBITDA if the acquisition grows at half the projected rate?

If you want to run this scorecard against your own acquisition pipeline or your existing brand portfolio before the next write-down quarter, that is a fractional CFO conversation. The analysis takes a few hours. The cost of not doing it arrives in the year the goodwill impairment hits your income statement.

Related teardowns and live indexes

For more CPG teardowns, read Simply Good Foods, BellRing Brands, and Freshpet. To benchmark Church & Dwight on margin and pricing power, track the Public DTC Leaderboard, the DTC Cost-of-Goods Index, and the DTC Inflation Pass-Through Gap.

Sources and methodology

SEC EDGAR is the primary source for every financial figure in this post. Church & Dwight Co., Inc. (CIK 0000313927) files on SEC EDGAR. The specific filings used: FY2025 10-K filing index (filed 2026-02-12, accession 0001193125-26-048139); FY2024 10-K filing index (filed 2025-02-13); FY2022 10-K filing index (filed 2023-02-16); Q1 2026 10-Q filing index (filed 2026-05-01). All impairment figures, revenue, gross margin, operating income, cash flow, goodwill, and segment data are from these primary filings.

The Touchland acquisition terms ($656.0M net of cash + $159.0M contingent earnout, closed July 16, 2025; 2024 Touchland net sales approximately $115M) are stated in the CHD 10-K FY2025 acquisition notes and MD&A. The ~$815M total consideration figure is the sum of these two disclosed amounts. See also the Touchland acquisition 8-K filing index (filed July 18, 2025).

Leadership transition disclosure is sourced to the CEO/CFO transition 8-K filing index (filed March 14, 2025, accession 0001193125-25-054846). The FY2025 10-K (filed February 12, 2026) was signed by Richard A. Dierker as President and Chief Executive Officer. Matthew T. Farrell retired as CEO effective April 2, 2025, when Dierker succeeded him per that 8-K. Lee McChesney became CFO effective March 24, 2025.

The VMS divestiture (VitaFusion and Lil Critters sold to Piping Rock Health Products, Inc., closed December 31, 2025, pre-tax loss $58.5M / post-tax $45.6M) is stated verbatim in the CHD 10-K FY2025 MD&A and Other income/expense note. Church & Dwight Q4 and FY2025 earnings release (January 30, 2026) at https://investor.churchdwight.com/Investors/news/news-details/2026/Church--Dwight-Reports-Q4-2025-and-2025-Results-and-Provides-2026-Outlook/default.aspx confirms the transaction and full-year figures.

The Flawless/Spinbrush/Waterpik showerhead exit ($45.6M pre-tax charge, approximately $118M annual net sales from those businesses) is stated verbatim in the CHD 10-K FY2025 MD&A: "On May 1, 2025, we announced that we would exit the Flawless, Spinbrush and Waterpik showerhead businesses."

Wall Street analyst consensus (Hold to Cautious Buy, mid-to-high $90s price target range) is synthesized from sell-side research notes and dated financial press, not from a single firm's primary published report. The directional characterization reflects aggregated analyst commentary available as of June 2026.

FY2026 guidance figures (+3% to +4% organic, -1.5% to -0.5% reported, +100bps adjusted gross margin, +5% to +8% adjusted EPS, approximately $1.15B operating cash flow) are from the CHD Q1 2026 earnings release (May 1, 2026) at https://investor.churchdwight.com/Investors/news/news-details/2026/Church--Dwight-Reports-Q1-2026-Results/default.aspx, which reaffirmed the guidance originally issued January 30, 2026.

Social signal is colour only. The three TikTok embeds in Section 2 are brand and category sentiment signals. @magdalenalook (3.2M plays, 32.1K likes) shows organic Batiste demand. @selina.dasilvaaa (1.3M plays, 61.7K likes) shows TheraBreath sponsored content placement. @blowoutprofessor (543K plays, 16.8K likes) shows category-level competitive commentary on Batiste quality. None are evidence of any revenue or margin figure.

Limitations. Church & Dwight does not separately disclose revenue by individual brand (Arm & Hammer, Hero, TheraBreath, etc. are not reported as standalone revenue lines in the 10-K). Organic underlying growth for FY2025 (+0.7%) is derived from CHD's disclosed growth components (volume +0.8%, price/mix -0.1%) as described in MD&A; CHD does not use the term "organic" as a formal reported metric. The net debt / EBITDA ratio cited (~1.5x) uses FY2025 operating cash flow as the denominator; a formal EBITDA calculation would differ. The Touchland acquisition earnout ($159M payable H1 2026) is recorded as a balance-sheet liability and is excluded from the $2,205.1M long-term debt figure. The goodwill and intangibles on the balance sheet ($2,627.5M goodwill + $3,511.5M intangibles = $6,139M combined, approximately 69% of total assets) reflect cumulative M&A premiums and are subject to annual impairment testing. This post reflects filings and disclosures current through June 25, 2026.

Frequently asked questions

what is church and dwight's revenue and how fast is it growing?

Church & Dwight reported $6,203.2M in FY2025 net sales, up +1.6% on a reported basis but only +0.7% on an organic underlying basis (volume +0.8%, price/mix -0.1%). The Touchland acquisition contributed +1.9% to reported growth; portfolio exits subtracted -1.0%. FY2026 guidance calls for reported sales of -1.5% to -0.5% (reflecting full-year portfolio pruning impact) with organic growth of +3% to +4%. Source: CHD 10-K FY2025; CHD Q1 2026 earnings release.

why did church and dwight write off $411 million on flawless and $357 million on vitafusion?

The Flawless $411.0M impairment (FY2022) reflected a collapse in demand for discretionary hair-removal devices after COVID-era peak demand reversed amid inflation; a major retailer also discontinued certain Flawless products. The VMS $357.1M impairment (FY2024) reflected structural category commoditization: the vitamins, minerals, and supplements market grew from roughly 10 significant competitors a decade ago to 50+ by 2024, including aggressive private-label entrants, destroying margins. Both brands were subsequently exited or divested. Source: CHD 10-K FY2022; CHD 10-K FY2024; CHD 10-K FY2025.

how much did church and dwight pay for touchland?

Church & Dwight acquired Touchland on July 16, 2025 for $656.0M net of cash, plus a contingent earnout of $159.0M payable in H1 2026 based on Touchland's 2025 net sales - total consideration of approximately $815M. Touchland's 2024 annual net sales were approximately $115M, implying a purchase price of roughly 7x trailing revenue. Touchland is the #1 US premium hand sanitizer brand and CHD's 7th power brand. Source: CHD 10-K FY2025, acquisition notes.

what are church and dwight's power brands?

As of December 31, 2025, Church & Dwight has seven power brands: Arm & Hammer, OxiClean, Batiste, Waterpik (flosser only - showerhead was exited), TheraBreath, Hero (Mighty Patch), and Touchland. These seven brands represent approximately 70% of CHD's net sales and profits. VitaFusion and Lil Critters were the eighth power brand until divested December 31, 2025. Source: CHD 10-K FY2025, Item 1.

what is church and dwight's gross margin?

Church & Dwight reported a 44.7% gross margin in FY2025 (-100bps versus 45.7% in FY2024). The reported decline was driven by exit-related costs (-50bps) and the lapping of a prior-year tariff refund (-50bps); adjusted gross margin was approximately 45.2%, flat year-over-year. Q1 2026 gross margin improved to 46.4% (+130bps adjusted), driven by productivity (+150bps), higher-margin acquisitions (+110bps), partially offset by tariff and inflation costs (-190bps). Source: CHD 10-K FY2025; CHD Q1 2026 earnings release.

how does church and dwight's acquisition history compare to its organic growth?

Since 2001, Church & Dwight has acquired 6 of its 7 current power brands. Over the FY2021-FY2025 period, acquired brands consistently contributed 2-4 points of reported growth annually, while underlying organic growth averaged roughly 1-4% - and declined to +0.7% in FY2025. In two of those five years (FY2022, FY2024), the acquisition engine produced major impairment charges ($411M and $357.1M respectively), revealing that M&A-fueled top-line growth can mask deteriorating brand fundamentals. Source: CHD 10-K filings FY2021-FY2025 (SEC EDGAR, CIK 0000313927).

is church and dwight a dividend aristocrat?

Yes. Church & Dwight has raised its annual dividend for 25+ consecutive years, qualifying as a Dividend Aristocrat. The FY2025 dividend was $1.18 per share ($0.295/quarter), up from $1.13 in FY2024 and $1.09 in FY2023. In FY2025, CHD also returned $900M through share buybacks - the largest buyback program in recent history. Total cash returned to shareholders in FY2025 was approximately $1,187M. Source: CHD 10-K FY2025.

what is the tariff risk to church and dwight's waterpik business?

Waterpik is one of CHD's seven power brands, but the flosser line was primarily sourced from China. The FY2025 10-K discloses that CHD has "substantially ceased the import of substantially all Waterpik flossers and certain other products from China into the U.S." in response to tariff escalation. CHD is mitigating by shifting production, relocating manufacturing, and seeking alternative sources. The Q1 2026 gross margin bridge showed -190bps from tariff and inflation costs, partially offset by productivity. Waterpik showerheads (separately) were exited in 2025. Source: CHD 10-K FY2025; CHD Q1 2026 10-Q.